Who Supplies Plasma to India from DENMARK

To import finished pharmaceutical formulations containing plasma into India, the foreign manufacturer must obtain an Import Registration Certificate from the Central Drugs Standard Control Organization (CDSCO). This process involves registering the manufacturing premises and the specific drug formulations. The registration certificate is valid for three years and is a prerequisite for obtaining an import license. The application must include a valid Good Manufacturing Practice (GMP) certificate, a Certificate of Pharmaceutical Product (COPP), and a Drug Master File (DMF). The registration process typically takes up to nine months from the date of application.

Imported pharmaceutical formulations containing plasma must undergo quality testing at CDSCO-approved laboratories in India. The importer is responsible for submitting three consecutive batches for testing, providing samples for reanalysis, and ensuring that the products meet the standards set by the Indian Pharmacopoeia. The Certificate of Analysis (CoA) from the exporting country’s laboratory must accompany the submission. The testing process includes stability studies in accordance with ICH Zone IV guidelines. Port inspection by customs drug inspectors is mandatory to verify compliance with regulatory standards.

In April 2025, the CDSCO mandated that all imported drugs, including finished formulations containing plasma, must have an Import Registration Certificate and an import license. This regulation aims to prevent the sale of unapproved or illegal medicines in the Indian market. The policy also stipulates that banned drugs manufactured in Special Economic Zones (SEZs) for export purposes are not permitted for transfer to the Domestic Tariff Area (DTA) for sale and distribution.

India imports finished pharmaceutical formulations containing plasma to meet the demand for specialized treatments not available domestically. These imports include patented or branded formulations and specific dosage forms that domestic manufacturers cannot produce. The Indian market for plasma formulations is valued at approximately $2.8 million, with 215 exporters supplying to 90 countries. The demand for imported plasma formulations is growing due to the increasing prevalence of conditions requiring such treatments.

The Basic Customs Duty (BCD) for HS Code 30029010, which covers human blood and related products, is 10%. An Education Cess of 2% and a Secondary Higher Education Cess of 1% are applicable, totaling 3%. The Social Welfare Surcharge (SWS) is 10% of the BCD, amounting to 1%. Integrated Goods and Services Tax (IGST) is levied at 18%. The total landed duty for imports under this HS code is approximately 10.3%.

Denmark is a significant supplier of finished pharmaceutical formulations containing plasma to India, with a total import value of $11.9K across six shipments. The top Danish suppliers include ELLEGAARD GOTTINGEN MINIPIGS A/S ($11.6K), SCANTOX A/S ($170), M S SCANTOX A S ($53), and MS SCANTOX A/S ($53). Denmark's competitive advantage lies in its high-quality manufacturing standards, adherence to international regulatory requirements, and the ability to supply specialized formulations not produced domestically. Other suppliers, such as China, Germany, and the United States, also export plasma formulations to India, but Denmark's reputation for quality and reliability positions it favorably in the market.

India imports finished pharmaceutical formulations containing plasma from Denmark due to the country's advanced pharmaceutical manufacturing capabilities, adherence to international quality standards, and the ability to produce specialized formulations not available domestically. Denmark's manufacturers offer patented formulations and specific dosage forms that meet the therapeutic needs of the Indian market, ensuring high efficacy and safety for patients.

Compared to other origins such as China, Germany, and the United States, Denmark offers a competitive edge in terms of product quality, regulatory compliance, and reliability. While China may offer lower prices, concerns about quality and regulatory standards can be a deterrent. Germany and the United States provide high-quality products but may have higher costs and longer lead times. Denmark's unique advantage lies in its balance of quality, cost-effectiveness, and timely delivery, making it an attractive sourcing option for Indian importers.

Indian importers face several supply chain risks when sourcing finished pharmaceutical formulations containing plasma from Denmark, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory developments, conduct regular quality audits, and maintain buffer stocks to manage potential shipping delays.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential shipping delays or supply disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial risks.
4. 4Supplier Qualification: Conduct thorough due diligence on potential suppliers, including audits of manufacturing facilities and reviews of quality certifications.
5. 5Regulatory Compliance: Ensure that all imported formulations comply with Indian regulatory standards and that necessary registrations and licenses are obtained.

1. Obtain Importer Exporter Code (IEC): Register with the Directorate General of Foreign Trade (DGFT) to obtain the IEC, a mandatory requirement for all importers.